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Abstract
Background: The breast is a rare extranodal site of non-Hodgkin lymphoma, and primary breast lymphoma (PBL) has 
been arbitrarily defined as disease localized to one or both breasts with or without regional lymph nodes involvement. 
The aim of this study was to evaluate the clinical outcomes in patients with diffuse large B cell lymphoma (DLBCL) and 
breast involvement, and to find the criteria of PBL reflecting the outcome and prognosis.
Methods: We retrospectively analyzed data from 68 patients, newly diagnosed with DLBCL and breast involvement at 
16 Korean institutions between January 1994 and June 2009.
Results: Median age at diagnosis was 48 years (range, 20-83 years). Forty-three (63.2%) patients were PBL according to 
previous arbitrary criteria, sixteen (23.5%) patients were high-intermediate to high risk of international prognostic 
index. The patients with one extranodal disease in the breast (OED) with or without nodal disease were 49 (72.1%), and 
those with multiple extranodal disease (MED) were 19 (27.9%). During median follow-up of 41.5 months (range, 2.4-
186.0 months), estimated 5-year progression-free survival (PFS) was 53.7 ± 7.6%, and overall survival (OS) was 60.3 ± 
7.2%. The 5-year PFS and OS was significantly higher for patients with the OED group than those with the MED group 
(5-year PFS, 64.9 ± 8.9% vs. 27.5 ± 11.4%, p = 0.001; 5-year OS, 74.3 ± 7.6% vs. 24.5 ± 13.0%, p < 0.001). In multivariate 
analysis, MED (hazard ratio [HR], 3.61; 95% confidence interval [CI], 1.07-12.2) and fewer than four cycles of systemic 
chemotherapy with or without local treatments (HR, 4.47; 95% CI, 1.54-12.96) were independent prognostic factors for 
worse OS. Twenty-five (36.8%) patients experienced progression, and the cumulative incidence of progression in 
multiple extranodal sites or other than breasts and central nervous system was significantly different between the OED 
group and the MED group (5-year cumulative incidence, 9.7 ± 5.4% vs. 49.0 ± 15.1%, p = 0.001).
Conclusions: Our results show that the patients included in OED group, reflecting different treatment outcome, 
prognosis and pattern of progression, should be considered as PBL in the future trial. Further studies are warranted to 
validate our suggested criteria.
Background
Approximately one-third of non-Hodgkin lymphoma
(NHL) arises primarily from sites other than lymph
nodes; for this reason, they are usually named as primary
extranodal lymphoma [1]. The definition of primary
extranodal lymphoma remains controversial, especially in
patients where both nodal and extranodal sites are
involved. In 1961, a strict definition for primary extran-
odal lymphoma was first proposed by Dawson et al. [2]
for primary gastrointestinal lymphoma, in which the pri-
mary disease was confined to the gastrointestinal tract
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with involvement of no more than regional lymph nodes.
Since then, some authors have suggested that a strict def-
inition of primary extranodal lymphoma, which excluded
patients with distant disease from the primary extranodal
site, may present an incomplete picture of extranodal
lymphoma [3-5]. Hence, more liberal criteria for primary
gastrointestinal lymphoma were proposed by other inves-
tigators. Lewin et al. [3] described a series of patients
with primary gastrointestinal lymphoma, which included
patients with contiguous other organ involvement and
distant nodal involvement as well as the gastrointestinal
tract, provided that the extranodal disease was just the
presenting site and constituted the predominant disease
bulk [6].
Breast lymphoma has been defined as lymphoma
involving the breast and historically has been classified
into primary breast lymphoma (PBL) and secondary
breast lymphoma (SBL). The criteria for PBL have been a
controversial, similar to those of other extranodal lym-
phomas. In 1972, Wiseman and Liao first proposed crite-
ria for PBL as follows: (1) adequate pathologic specimens;
(2) mammary tissue and lymphomatous infiltrate in close
association; (3) no prior diagnosis of an extramammary
lymphoma; and (4) no evidence of concurrent widespread
disease except ipsilateral axillary lymph nodes [7]. All
patients not meeting these four criteria were considered
to have SBL. According to these criteria, all patients with
PBL had localized disease with or without regional lymph
node involvement.
This strict definition for PBL has been adopted in most
subsequent clinical studies or case reports for this rare
extranodal lymphoma. However, the clinical study that
provided data in developing the defining criteria had sev-
eral limitations. The study included a total of 31 patients
and evaluated only 16 patients with PBL. This, we
thought, was an extremely small number of patients to
define criteria for classification. In addition, differences in
clinical parameters and treatment outcomes between
PBL and SBL were not described. As mentioned above,
some investigators asserted that these strict criteria did
not reflect the biologic behavior of the disease, rather
only representing a localized manifestation of a different
primary extranodal lymphoma [3-5]. In fact, the tradi-
tional strict criteria adopted the pattern of spread that
was seen in epithelial breast tumors, from the breast to
the regional lymph nodes, even though the pattern of
spread in NHL might be different from that of epithelial
breast tumors. These findings strongly suggest that the
traditional strict criteria for breast lymphoma are not
based on scientific considerations about the tumor, but
on arbitrary decisions. Nevertheless, until recently, there
has been a lack of research investigating more scientific
criteria that reflect differences in treatment outcomes
and prognosis in patients with NHL and breast involve-
ment.
Therefore, we conducted this retrospective study to
investigate scientific classification criteria of primary and
secondary breast diffuse large B cell lymphoma (DLBCL)
that would reflect treatment outcomes and prognosis. We
also evaluated the treatment outcomes of patients with
PBL according to the new suggested criteria in terms of
progression-free survival (PFS) and OS.
Methods
Patients
We consecutively enrolled 68 patients who were newly
diagnosed with DLBCL with breast involvement at 16
Korean institutions between January 1994 and June 2009.
The two main eligibility criteria included: (1) The histo-
logic diagnosis of DLBCL. The histologic subtypes were
classified according to the World Health Organization
(WHO) classification, but the Revised European-Ameri-
can Lymphoma (REAL) classification was used before the
WHO classification was published in 2001. (2) Documen-
tation of involvement of one or both breasts by the lym-
phoma, by histology or imaging modalities such as
computed tomography or positron emission tomography
if other sites were biopsied as needed. Patients presenting
with recurrent lymphoma in the breast following prior
treatment were excluded. According to the traditional
strict criteria, PBL was defined as disease localized to one
or both breasts with or without regional lymph nodes
involvement (ipsilateral axillary and/or supraclavicular
lymph nodes), and SBL was defined as disease with sys-
temic lymph nodes and/or other extranodal organ
involvement as well as involvement of one or both
breasts. Mediastinal and cervical lymph nodes were not
r e g a r d e d  a s  r e g i o n a l  l y m p h  n o d e s .  B o n e  m a r r o w  w a s
considered an extranodal site. By the number of involved
extranodal disease, one extranodal disease in the breast
(OED) was defined as disease with only breast involve-
ment with or without nodal disease, which included dis-
tant systemic nodal disease as well as regional nodal
disease. Multiple extranodal disease (MED) was defined
as disease with multiple extranodal organ involvement
including one or both breasts regardless of any involve-
ment of lymph nodes (Table 1). Namely, the MED group
included patients who had two or more extranodal dis-
ease sites including one or both breasts. The patients
were staged according to the Ann Arbor staging system,
and the International Prognostic Index (IPI) was deter-
mined for prognosis. Other clinical characteristics,
including demographics, laboratory profiles, disease-
related profiles, treatment, and treatment outcomes were
collected using study-specific case record forms. This
study protocol was approved by the Institutional Review
Board (IRB) from each participating institution.Yhim et al. BMC Cancer 2010, 10:321
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Criteria for Treatment Outcomes
Tumor response was evaluated using the International
Working group Criteria (IWC) [8]. PFS was defined as
the time from the first day of treatment to the date on
which progressive disease was first documented or to the
date of last follow-up. OS was calculated as the time from
the first day of treatment to the date of death or the date
of last follow-up.
Statistical Analysis
Descriptive statistics were summarized as frequencies
and percentages for categorical variables and as median
and range for continuous variables. The comparisons of
clinical variables between the OED group and MED
group were made using χ2 test or Fisher's exact test for
categorical variables, and Mann-Whitney test for contin-
uous variables. The distribution of PFS and OS was esti-
mated using the Kaplan-Meier method, and comparisons
between groups were made using log-rank tests. Multi-
variate analysis was carried out using the Cox propor-
tional hazards models, reported with hazard ratio (HR)
and 95% confidence interval (CI), and a significance level
of 0.05 was used for covariate entry. The cumulative inci-
dence of first progression according to the predominant
sites was estimated using the Kalbfleisch and Prentice
method [9]. Two-tailed p value of <0.05 was considered
statistically significant. SPSS for windows, version 12.0
(SPSS Inc., Chicago, IL, USA), was used for all statistical
analyses.
Results
Demographic and Clinical Characteristics
Demographic and clinical characteristics of these 68
patients are summarized in Table 2. The median age at
diagnosis was 48 years (range, 20-83 years) and all
patients were female. Forty-five (66.2%) patients were
localized stages (I/II), 26 (38.2%) patients elevated level of
lactate dehydrogenase (LDH) and 5 (7.4%) patients had B
symptoms. Sixteen (23.5%) patients were classified as
high-intermediate to high risk according to the IPI. Two
(2.9%) patients were bulky at diagnosis. Sixty-seven
(98.5%) patients were treated with systemic chemother-
apy, 66 (97.1%) treated with anthracycline-based regi-
mens. Fifty-five (80.9%) patients were treated with four or
more than four cycles of systemic chemotherapy with our
without any local treatment modalities such as surgery or
radiotherapy. Any surgery or radiotherapy to the breasts
was performed in 23 (33.8%) and 21 (30.9%) patients,
respectively. Forty-two patients (61.8%) were received
immunochemotherapy with rituximab.
According to the number of involved extranodal organ,
the OED group included 49 (72.1%) patients, and the
MED group included 19 (27.9%) patients. By definition,
all patients in the MED group were Ann Arbor stage IV
disease and had at least two clinical risk factors for IPI,
more than one site of extranodal disease and stage. The
m e d i a n  n u m b e r  o f  i n v o l v e d  e x t r a n o d a l  o r g a n  i n  M E D
group was 3 (range, 2-5). The most commonly involved
extranodal organs except breast were liver and bone (n =
6, 31.6%, respectively), which were followed by lung (n =
4), bone marrow (n = 4), stomach (n = 3), nasal cavity (n =
3), central nervous system (n = 3), adrenal gland (n = 2),
pancreas (n = 2), thyroid (n = 1) and ovary (n = 1).
Patients in the OED group were Ann Arbor stage I to III,
and all PBL patients according to the traditional strict cri-
teria were included in the OED group. As a result, more
patients in the OED group had low to low-intermediate
IPI than in the MED group (89.8% vs. 31.6%, p < 0.001).
When we compared the classification according to the
number of involved extranodal organ with the traditional
strict criteria, six patients diagnosed with SBL by the tra-
ditional strict criteria included into the OED group. Of
the six patients, four patients were stage III, and two
patients were stage II; five patients had low to low-inter-
mediate of IPI, and one patient had high to high-interme-
diate IPI. Treatment with fewer than four cycles of
systemic chemotherapy following surgery or followed by
radiotherapy did not differ between the two groups.
Among 21 patients treated with surgery in the OED
group, modified radical mastectomy was performed in 13
(61.9%) patients and lumpectomy with or without axillary
node dissection, in 8 (38.1%) patients. The MED group
received rituximab more frequently than OED group
(84.2% vs. 53.1%, p = 0.025) (Table 2).
Treatment Outcomes
Response data for initial treatment were available for 65
(95.6%) patients. Two patients could not be evaluated for
response because of systemic chemotherapy at the time
of analysis, and one patient could not be determined due
to treatment-related septic death before response evalua-
Table 1: Classification of breast lymphoma according to the 
number of involved extranodal organs
Definition
OED Isolated extranodal organ (i.e. breast) involvement 
with or without nodal disease, which included distant 
systemic nodal disease as well as regional nodal 
disease.
MED Multiple extranodal organ involvement including one 
or both breasts regardless of any involvement of 
lymph nodes
Abbreviations: OED, one exgtranodal disease in the breast; MED, 
multiple extranodal disease.Yhim et al. BMC Cancer 2010, 10:321
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Table 2: Demographics and clinical characteristics of 68 patients
Characteristics Total (n = 68) OED (n = 49) MED (n = 19) P value
Age at diagnosis, year
Median 48 45 52 0.589
Range 20-83 20-73 20-83
Sex
Male 0 0 0
Female 68 49 19
Duration of follow-up, months
Median 41.5 46.3 34.7 0.176
Range 2.4-186.0 2.4-186.0 2.5-123.5
Ann Arbor stage
I-II 45 (66.2%) 45 (91.8%) 0 (0%) <0.001
III-IV 23 (33.8%) 4 (8.2%) 19 (100%)
B symptoms
Absent 63 (92.6%) 47 (95.9%) 16 (84.2%) 0.129
Present 5 (7.4%) 2 (4.1%) 3 (15.8%)
ECOG performance status
0-1 63 (92.6%) 47 (95.9%) 16 (84.2%) 0.129
2-3 5 (7.4%) 2 (4.1%) 3 (15.8%)
LDH level
Normal 36 (52.9%) 29 (59.2%) 7 (36.8%) 0.098
Elevated 26 (38.2%) 16 (32.7%) 10 (52.6%)
Unknown 6 (8.8%) 4 (8.1%) 2 (10.5%)
IPI
Low to low-intermediate 50 (73.5%) 44 (89.8%) 6 (31.6%) <0.001
High-intermediate to high 16 (23.5%) 3 (6.1%) 13 (68.4%)
Unknown 2 (2.9%) 2 (4.1%) 0 (0%)
Traditional strict criteria
Traditional PBL 43 (63.2%) 43 (87.8%) 0 (0%) N/A
Traditional SBL 25 (36.8%) 6 (12.2%) 19 (100%)
Bulky disease
No 66 (97.1%) 48 (98.0%) 18 (94.7%) 0.484
Yes 2 (2.9%) 1 (2.0%) 1 (5.3%)
Systemic chemotherapy
No 1 (1.5%) 0 (0%) 1 (5.3%) 0.279
Yes 67 (98.5%) 49 (100%) 18 (94.7%)
Surgery of the breast
No 45 (66.2%) 28 (57.1%) 17 (89.5%) 0.012
Yes 23 (33.8%) 21 (42.9%) 2 (10.5%)
Radiotherapy to the breast
No 47 (69.1%) 29 (59.2%) 18 (94.7%) 0.004
Yes 21 (30.9%) 20 (40.8%) 1 (5.3%)
Treatment strategy
<4 cycles ± local modalities 12 (17.6%) 8 (16.3%) 4 (21.1%) 0.577Yhim et al. BMC Cancer 2010, 10:321
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tion. Complete response occurred in 54 (83.1%) patients,
and partial response, in six (9.2%) patients, for an overall
response of 92.3% with initial treatment. Overall
response was significantly higher in the OED group
(97.9%) than in the MED group (76.5%, p = 0.015).
With median follow-up of 41.5 months (range, 2.4-
186.0 months), estimated 5-year PFS was 53.7 ± 7.6% and
OS was 60.3 ± 7.2%. Univariate analysis of factors influ-
encing PFS and OS is presented in Table 3. In univariate
analysis for PFS, Ann Arbor stage of III or IV, ECOG per-
formance status of 2 or 3, elevated levels of LDH, high-
intermediate to high IPI, the SBL group according to tra-
ditional strict criteria, the MED group and fewer than
f o u r  cy c l e s  o f  s y s t e m i c  c h e m o t h e r a p y  w i t h  o r  w i t h o u t
local treatment were significantly associated with lower
PFS (Table 3). In multivariate analysis for PFS, indepen-
dent prognostic factors for lower PFS included the MED
group (HR, 4.11; 95% CI, 1.28-13.2), a high-intermediate
to high IPI (HR, 3.35; 95% CI, 1.05-10.72) and fewer than
f o u r  cy c l e s  o f  s y s t e m i c  c h e m o t h e r a p y  w i t h  o r  w i t h o u t
local treatment (HR, 3.90; 95% CI, 1.30-11.70) (Table 4).
In univariate analysis for OS, Ann Arbor stage of III or
IV, ECOG performance status of 2 or 3, elevated levels of
LDH, high-intermediate to high IPI, the SBL group
according to traditional strict criteria, the MED group,
and fewer than four cycles of systemic chemotherapy
with or without local treatment were significantly associ-
ated with lower OS (Table 3). In multivariate analysis for
OS, the MED group (HR, 3.61; 95% CI, 1.07-12.2) and
fewer than four cycles of systemic chemotherapy with or
without local treatment (HR, 4.47; 95% CI, 1.54-12.96)
were independent prognostic factors for lower OS (Table
4). Other risk factors of earlier death included in multi-
variate model were IPI (high-intermediate to high) and
traditional strict criteria (SBL). However, these variables
were not independent prognostic factors for OS. Immu-
nochemotherapy with rituximab was not associated with
improved PFS or OS.
In the subgroup analysis of the OED group according to
the number of involved extranodal organ, the patients
who had fewer than four cycles of systemic chemotherapy
had significantly worse 5-year PFS and OS, compared
with patients with four or more cycles of systemic che-
motherapy (5-year PFS, 40% vs. 68.6%, p = 0.016; 5-year
OS, 30% vs. 79.6%, p = 0.003, Figure 1A) However, we
found that the use of immunochemotherapy with ritux-
imab, surgery, and radiotherapy were not associated with
differences in PFS and OS (Figure 1B, C, D)
≥4 cycles ± local modalities 55 (80.9%) 41 (83.7%) 14 (73.6%)
No treatment 1 (1.5%) 0 (0%) 1 (5.3%)
Rituximab use
No 26 (38.2%) 23 (46.9%) 3 (15.8%) 0.025
Yes 42 (61.8%) 26 (53.1%) 16 (84.2%)
Enroll period
1994-2002 21 (30.9%) 19 (38.8%) 2 (10.5%) 0.039
2003-2009 47 (69.1%) 30 (61.2%) 17 (89.5%)
Extranodal involvement
Breast 68 (100%) 49 (100%) 19 (100%) N/A
Liver 6 (8.8%) 0 6 (31.6%)
Bone 6 (8.8%) 0 6 (31.6%)
Lung 4 (5.9%) 0 4 (21.1%)
Bone marrow 4 (5.9%) 0 4 (21.1%)
Stomach 3 (4.4%) 0 3 (15.8%)
Nasal cavity 3 (4.4%) 0 3 (15.8%)
Central nervous system 3 (4.4%) 0 3 (15.8%)
Adrenal gland 2 (2.9%) 0 2 (10.5%)
Pancreas 2 (2.9%) 0 2 (10.5%)
Thyroid 1 (1.5%) 0 1 (5.3%)
Ovary 1 (1.5%) 0 1 (5.3%)
Values are expressed as the number of patients (%) unless stated otherwise. Abbreviations: OED, one exgtranodal disease in the breast; MED, 
multiple extranodal disease; PBL, primary breast lymphoma; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, 
international prognostic index; SBL, secondary breast lymphoma; BM, bone marrow.
Table 2: Demographics and clinical characteristics of 68 patients (Continued)Yhim et al. BMC Cancer 2010, 10:321
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Table 3: Univariate analysis of prognostic factors for progression-free survival and overall survival
Variables No. of patients 5-year PFS
(95% CI)
P value 5-year OS
(95% CI)
P value
Age at diagnosis (years)
<60 55 54.0 ± 8.1 0.943 61.6 ± 7.8 0.616
≥60 13 58.2 ± 17.0 57.3 ± 17.0
Ann Arbor stage
I-II 45 61.3 ± 9.2 0.038 70.7 ± 8.0 0.010
III-IV 23 38.5 ± 11.9 35.1 ± 13.8
B symptoms
No 63 54.3 ± 7.8 0.288 61.8 ± 7.4 0.088
Yes 5 50.0 ± 25.0 50.0 ± 25.0
ECOG performance status
0-1 63 55.8 ± 7.9 0.016 63.4 ± 7.4 0.015
2-3 5 40.0 ± 21.9 25.0 ± 21.7
LDH level
Normal 36 68.3 ± 11.2 0.007 71.0 ± 8.9 0.049
Elevated 26 36.1 ± 11.8 40.1 ± 12.3
No. of involved extranodal organ
OED 49 64.9 ± 8.9 0.001 74.3 ± 7.6 <0.001
MED 19 27.5 ± 11.4 24.5 ± 13.0
IPI
Low to low-intermediate 50 63.2 ± 9.1 <0.001 69.2 ± 8.1 0.001
High-intermediate to high 16 25.0 ± 12.3 23.6 ± 13.7
Traditional strict criteria
Traditional PBL 43 89.4 ± 5.9 0.008 72.6 ± 8.0 0.008
Traditional SBL 25 61.7 ± 12.8 33.3 ± 13.4
Radiotherapy to the breast
No 47 58.4 ± 8.5 0.777 56.6 ± 9.4 0.477
Yes 21 51.8 ± 12.0 66.7 ± 11.3
Surgery of breast
No 45 53.4 ± 9.6 0.839 58.6 ± 9.7 0.582
Yes 23 57.2 ± 11.5 64.1 ± 10.9
Treatment strategy
<4cycles ± any local modalities 12 28.0 ± 16.4 <0.001 19.3 ± 16.2 <0.001
≥4cycles ± any local modalities 55 58.0 ± 8.3 66.2 ± 7.7
Rituximab use
No 26 56.8 ± 11.3 0.366 60.6 ± 10.3 0.975
Yes 42 53.5 ± 9.5 60.3 ± 10.3
Abbreviations: PFS, progression-free survival; OS, overall survival; CI, confidence interval; ECOG Eastern Cooperative Oncology Group; LDH, 
lactate dehydrogenase; PBL, primary breast lymphoma; OED, one extranodal disease in the breast; MED, multiple extranodal disease; IPI, 
international prognostic index; SBL, secondary breast lymphoma.Yhim et al. BMC Cancer 2010, 10:321
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Patterns of Progression
Twenty-five (36.8%) patients experienced progressive dis-
ease following first-line treatment, and nine (13.2%)
patients had two or more organs involved at first progres-
sion. Lymph nodes were a first site of progression in 10
patients, breast in nine, CNS in seven, intestine in three,
lung in three, bone marrow in two, and liver, nasal cavity,
ovary, adrenal gland each in one patient. Table 5 repre-
sents the cumulative incidence of progression at each
predominant involvement site. When the cumulative
incidence of progression of lymph nodes only, breasts
(with or without lymph nodes, with or without CNS) and
CNS (with or without lymph nodes, with or without
other extranodal disease, but not lymph nodes only and
breast) were compared between the OED and MED
groups, they were not significantly different, whereas the
cumulative incidence of extranodal progression in two or
more sites or other than breasts and CNS was signifi-
cantly higher in the MED group than in the OED group.
Breast was the most common site of first progression in
the OED group (six patients, 12.2%). And, CNS was a first
progression site in five (10.2%) patients among 49
patients in the OED group. Five (10.2%) patients in the
OED group were treated with prophylactic intrathecal
chemotherapy, and there was no CNS progression in
these patients.
Discussion
PBL is a rare clinical presentation of NHL with a preva-
lence of 0.04% to 1.1% of all breast tumors and 1.7% to
2.2% of all extranodal NHL [10]. However, the definition
of PBL is still unclear. Criteria for PBL were first pro-
posed by Wiseman and Liao in 1972 [7], which were
ambiguous and arbitrary criteria that did not consider the
biologic behavior of NHL and were not validated as to
prognostic significance.
In this study, we evaluated clinical parameters, treat-
ment outcomes, prognostic factors, and patterns of pro-
gression in patients with DLBCL of the breast, and found
the classification by the number of involved extranodal
organ, OED group and MED group, could reflect the dif-
ferences. According to the suggested classification crite-
Table 4: Multivariate analysis of prognostic factors for progression-free survival and overall survival
Variables Hazard ratio 95% CI P value
PFS
No. of involved extranodal organ
OED 1
MED 4.11 1.28-13.2 0.017
IPI
Low to low-intermediate 1
High-intermediate to high 3.35 1.05-10.72 0.042
Treatment strategy
≥4cycles ± any local modalities 1
<4cycles ± any local modalities 3.90 1.30-11.70 0.015
OS
No. of involved extranodal organ
OED 1
MED 3.61 1.07-12.20 0.039
IPI
Low to low-intermediate 1
High-intermediate to high 3.58 0.99-12.98 0.052
Treatment strategy
≥4cycles ± any local modalities 1
<4cycles ± any local modalities 4.47 1.54-12.96 0.006
Abbreviation: PFS, progression-free survival; OS, overall survival; CI, confidence interval; OED, one extranodal disease in the breast; MED, 
multiple extranodal disease; IPI, international prognostic index.Yhim et al. BMC Cancer 2010, 10:321
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Figure 1 Kaplan-Meier survival curves of PFS (left) and OS (right) by each type of treatment in the OED group. (A) By number of cycles of sys-
temic chemotherapy (fewer than four versus four or more); (B) the use of rituximab; (C) surgery, and (D) radiotherapy. Abbreviations: PFS, progression-
free survival; OS, overall survival; OED, one extranodal disease in the breast.Yhim et al. BMC Cancer 2010, 10:321
http://www.biomedcentral.com/1471-2407/10/321
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ria, all patients in the MED group were Ann Arbor stage
IV, whereas patients in the OED group were Ann Arbor
stages I to III. As a result, more patients in the OED
group had low to low-intermediate IPI than in the MED
group. When we compared traditional strict criteria with
our suggested criteria, 5-year PFS in the MED group were
markedly lower than in the SBL group (5-yr PFS, 27.5 ±
11.4% vs. 61.7 ± 12.8%). This may indicate that some pro-
portion of patients in the traditional SBL group have a
relatively favorable treatment outcome and probably a
different biology than those who had MED. Furthermore,
although both the criteria by the number of involved
extranodal organ and the traditional strict criteria
showed statistically significant differences by univariate
analysis, only the criteria according to the number of
involved extranodal organ were an independent factor for
predicting PFS and OS by multivariate analysis. Thus, the
classification according to the number of involved extran-
odal organ had better discriminatory power for predict-
ing survival by separating the patients who had a
favorable outcome in the SBL group without conflating
the different clinical characteristics and treatment out-
comes between PBL and SBL seen in the traditional strict
criteria. Moreover, comparing the predominant sites of
progression in the OED and MED groups, interesting fea-
tures were observed. Patients in the MED group were sig-
nificantly more likely to have multiple extranodal organ
recurrence, compared with the OED group. On the other
hand, breast (six patients, 12.2%) was the most common
site of progression in the OED group, indicating that the
patterns of progression may be different according to the
number of extranodal organ. Therefore, the OED group
according to the number of involved extranodal organ
should be considered as PBL in the subsequent clinical
studies, because this could reflect the differences in treat-
ment outcome, prognosis and patterns of progression.
It was an interesting finding that rituximab was not
associated with improved outcome in our cohort. It
might be related with the fact that the MED group
received rituximab more frequently than OED group. In
our country, rituximab was available since 2003. From
1994 to 2002, twenty-one patients were consecutively
enrolled to this study, and they, of course, were treated
without rituximab. Of these patients, 19 patients were the
OED group, whilst only 2 patients were the MED group
(p = 0.039). This might explain why the MED group
received rituximab more frequently than OED group. On
the long-term results of pivotal trial about rituximab con-
ducted by the Groupe d'Etude des Lymphomes de l'Adulte
(GELA), immunochemotherapy with rituximab showed
the significant superiority of OS over chemotherapy
alone in low-risk patients according to age-adjusted IPI
[11]. However, the difference of OS in high-risk patients
was not evident. The MED group, in our analysis, was
absolutely poor-risk group because about two-thirds of
patients were high-intermediate to high risk according to
IPI. Therefore, the lack of impact on OS of rituximab
might be associated with fact that rituximab was more
frequently used in poor-risk patients.
The prognostic relevance of the IPI in patients with
breast lymphoma has been validated in several studies
[12,13]. The IPI in our population was also an indepen-
dent prognostic factor for PFS but not for OS. Our study
had relatively short follow-up duration (median 41.5
Table 5: Comparison of cumulative incidence of predominant progression sites between one extranodal disease in the 
breast and multiple extranodal disease group according to suggested criteria
Disease classification No. 1-year 3-year 5-year P value
LNs only OED 1 2.7 ± 2.7 2.7 ± 2.7 2.7 ± 2.7 0.062
MED 2 7.7 ± 7.4 10.2 ± 8.2 10.2 ± 8.2
Breast (±LNs, ±CNS) OED 6 7.8 ± 4.3 11.9 ± 5.8 16.6 ± 7.1 0.902
MED 2 13.7 ± 9.2 13.7 ± 9.2 13.7 ± 9.2
CNS (±LNs, ± other extranodal 
diseases, but not LNs only and
OED 4 5.5 ± 3.8 8.7 ± 4.8 12.3 ± 8.5 0.411
breast) MED 2 12.5 ± 8.3 12.5 ± 8.3 12.5 ± 8.3
Extranodal diseases (±LNs, ≥2 or 
other than
OED 3 2.9 ± 2.8 9.7 ± 5.4 9.7 ± 5.4 0.001
breast and CNS) MED 6 38.7 ± 14.2 49.0 ± 15.1 49.0 ± 15.1
Values are expressed as cumulative incidence (%) ± standard error unless stated otherwise. Abbreviations: OED, one extranodal disease in the 
breast; MED, multiple extranodal disease; LNs, lymph nodes; CNS, central nervous system.Yhim et al. BMC Cancer 2010, 10:321
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months). As a result, only 10 (20.4%) patients in the PBL
group had died by the time of analysis. Because of this
point, further follow-up is needed to evaluate the influ-
ence of IPI on OS.
Recently, the International Extranodal Lymphoma
Study Group (IELSG) reported the results of the largest
international survey to date of 204 patients with primary
localized DLBCL of the breast, in which the study
adopted traditional strict criteria for PBL [12]. When we
compared the survival of our PBL group, which indicated
OED group according to the number of involved extran-
odal organ, with outcomes seen in the IELSG survey, 5-
year PFS (64.9%) and OS (74.3%) in our cohort were supe-
rior to those in IELSG survey (54% and 63%, respec-
tively), even though direct comparison is difficult because
of the different definitions of PBL. The relatively good
survival in our PBL group may reflect different patient
characteristics, compared with those from the IELSG
survey. The median age in our cohort (45 years) was
younger than that in the IELSG survey (64 years), and the
proportion of patients with low to low-intermediate IPI
in our cohort (89.8%) was higher than in the IELSG
cohort (78%). The patients in our cohort may have more
favorable prognostic indices, compared with those in the
IELSG survey, and this was associated with more favor-
able survival even though the patients with more
advanced stages were included in our PBL group.
Our study also confirmed the previously reported high
rate of extranodal recurrence in the PBL [10,12-17]. The
sites of progression in the OED group were mainly extra-
nodal. Only one patient had progression in lymph nodes
without extranodal disease. One of the notable findings
in our analysis was relatively high risk of CNS progres-
sion in the OED group, even with relatively short follow-
up duration. In our analysis, CNS progression occurred
in 10.2% of patients in the PBL group. Although consider-
ably lower CNS progression (5%) occurred in the IELSG
survey [12], other PBL series consistently showed more
than 10% of CNS progression [10,13-15,17]. Further-
more, other extranodal primary DLBCL, such as primary
testicular DLBCL, has a high risk of CNS progression of
approximately 15% up to10 years [18]. Concerns about
l a t e  CNS  p r ogr e s s i o n  i n  pa t i e n ts  wi t h  e x t r a n oda l  l ym -
phoma, in contrast to early relapse within 1 year in
patients with aggressive nodal lymphoma, were raised in
this primary testicular series [18]. Although it is not clear
whether late CNS progression is a unique characteristic
of primary testicular lymphoma or a common feature of
extranodal lymphoma, we cannot exclude the possibility
of further CNS progression in our cohort. Additionally, it
is an interesting finding that CNS progression did not
occur in the five patients who received prophylactic
intrathecal chemotherapy. Although the value of prophy-
lactic intrathecal chemotherapy could not be evaluated in
this analysis because of the small number of patients, we
thought this may be a meaningful finding when we con-
sidered that no CNS progression occurred in a subgroup
of patients who received prophylactic intrathecal chemo-
therapy in the IELSG survey as well [12]. Thus, further
studies are needed to provide solid evidence to support
the use of prophylactic intrathecal chemotherapy in
patients with PBL.
There is still no universal standard treatment of PBL.
Most studies agree that the combination of limited sur-
gery, anthracycline-based systemic chemotherapy, and
radiotherapy is the best therapeutic option in patients
with PBL [12,13,17]. Interestingly, more than four cycles
of anthracycline-based systemic chemotherapy was asso-
ciated with improved PFS and OS in the PBL group,
whereas radiation therapy was not associated with
improved PFS and OS. This observation may be quite dif-
ferent from previous PBL series, which reported that
radiation therapy was associated with survival benefit
[12,13]. However, our results about radiation therapy
should be interpreted with caution because a high pro-
portion of patients (61.9%) in PBL group were treated
with modified radical mastectomy. Several studies
reported that survival was not improved by surgery in
patients with PBL [12,16,19]. Furthermore, the IELSG
reported that radical mastectomy, which caused delayed
initiation of systemic chemotherapy, was associated with
poorer survival [12]. In our study, the proportion of
patients treated with modified radical mastectomy was
more than twice that of the IELSG survey (30%), and this
factor might offset the merits of radiation therapy. Also,
an abbreviated course of systemic chemotherapy as well
as extensive surgery might influence the poorer survival
in our analysis. A randomized trial, comparing a full
course of cyclophosphamide, doxorubicin, vincristine,
and prednisolone (CHOP) alone with an abbreviated
course of CHOP followed by involved-field radiotherapy
(IFRT) in patients with nonbulky, stage I-II, nodal
DLBCL, was conducted by the Southwest Oncology
Group, and the abbreviated course of CHOP plus radio-
therapy was superior to full course CHOP alone, with
median follow-up of 4.4 years [20]. However, an update of
that study with longer follow-up showed convergence of
survival curves as a result of an excess of relapses and
deaths from lymphoma in the group given the abbrevi-
a t e d  c o u r s e  o f  C H O P  p l u s  I F R T  [ 2 1 ] .  T h e  a u t h o r s
explained that these results might be associated with the
inclusion of patients with adverse prognostic factors,
s u c h  a s  e l e v a t e d  L D H  l e v e l s  s e e n  i n  2 0 %  o f  p a t i e n t s .
Thus, the Southwest Oncology Group study emphasized
the significance of systemic chemotherapy in patients
with adverse prognostic factors. Our analysis included
about one-third of patients with elevated levels of LDH in
the OED group, and it is likely that an abbreviated courseYhim et al. BMC Cancer 2010, 10:321
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of systemic chemotherapy negatively influenced the out-
come in these patients.
Generally, the addition of rituximab to chemotherapy
has improved of survival in patients with aggressive nodal
DLBCL [22,23]. However, the impact on survival of ritux-
imab has never been studied in patients with PBL. Persky
et al. [24] reported that the addition of rituximab to three
cycles of CHOP plus IFRT in patients with high-risk, lim-
ited-stage DLBCL, r esulted in modest im provement of
PFS and OS compared with historical cohort. In that
study, high-risk patients were defined as those with at
least one adverse risk factor by the stage-modified IPI
(nonbulky stage II disease, age >60 years, WHO perfor-
mance status of 2, or elevated serum LDH). However, this
improvement was smaller than observed in advanced dis-
ease, and they hypothesized that the modest improve-
ment might be related with a unique biology of limited-
stage DLBCL contrast to advanced-stage disease. This
finding was meaningful for us to infer the role of ritux-
imab in patients with PBL. More than two-thirds (71.4%)
in the OED group of our cohort were high-risk, limited-
stage disease. And thus, it was likely that rituximab in
patients with PBL might add smaller benefit than as we
expected. Furthermore, there was a report suggesting
that survival benefits with rituximab were not evident in
patients with PBL, in which patients were treated with
rituximab and dose-dense chemotherapy (CEOP14) and
compared with historical controls [25]. In our analysis of
OED group, they did not show a significant PFS differ-
ence between patients with chemotherapy plus rituximab
and those with chemotherapy alone, but only showed a
trend of improved OS for patients treated with chemo-
therapy plus rituximab. In contrast to nodal, advanced
DLBCL, limited role of immunochemotherapy with
rituximab would be suggested in this rare extranodal
DLBCL. Thus, even though success of rituximab in nodal,
advanced-stage DLBCL, further studies are needed for
demonstrating the efficacy of rituximab in patients with
PBL.
The limitations of the current study include the follow-
ings. First, the small number of patients, heterogeneity of
the population and short follow-up duration are impor-
tant limitations of this study. Second, molecular prognos-
tic phenotypes such as germinal center (GC) and
activated B cell were not included in this analysis because
study protocol approved by IRBs of each center did not
require mandatory tissue collection. Recently, some stud-
ies have reported that GC phenotype of DLBCL have a
significantly better outcome compared to patients with
the non-GC phenotype [26,27]. However, other studies
suggested that the addition of rituximab to CHOP-like
chemotherapy was associated with overcoming the
adverse prognostic impact of non-GC phenotype [28,29].
About two-thirds of patients (61.8%) in our analysis were
treated with rituximab-containing regimens. Therefore, it
was likely that the influence of molecular phenotypes on
prognosis would quite be decreased in our cohort. None-
theless, it is major limitation that the results of molecular
phenotypes on this series of patients are not available.
As we stated above, several questions about treatment
strategies of PBL were raised in this retrospective analy-
sis. Solid evidence, as we know, should come from the
results of randomized trials designed on the basis of find-
ings from retrospective studies. The rarity of the disease,
however, makes randomized trials virtually impossible in
a single institution or nation. Hence, international collab-
oration is required to adequately conduct randomized tri-
als. F uture trials for PBL should consider adopting the
criteria according to the number of involved extranodal
organ, and include questions raised in our study, includ-
ing the role of rituximab, prophylactic intrathecal chemo-
therapy, and radiation therapy. The results of such trials
can provide evidence to define the best treatment strate-
gies for PBL.
Conclusions
In conclusion, our analysis showed classification criteria
for PBL reflecting differences in treatment outcomes,
prognosis and patterns of progression, compared with the
traditional strict criteria. A full course of anthracycline-
c o n t a i n i n g  s y s t e m i c  c h e m o t h e r a p y  a p p e a r e d  t o  b e  t h e
most important treatment for patients with PBL. How-
ever, we also found that extensive radical surgery might
be harmful and therefore should be avoided. Neverthe-
less, extranodal progression, especially in the breast and
CNS, is the main reason for treatment failure in patients
with PBL, resulting in shorter long-term survival. Further
studies of prospective design with international collabo-
ration are warranted to evaluate the role of rituximab,
prophylactic intrathecal chemotherapy, and radiation
therapy in patients with PBL according to our suggested
criteria.
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